Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic therapy but have not undergone gemcitabine-based treatment.
Pancreatic Cancer Non-resectable|Pancreatic Cancer Metastatic
DRUG: Adebrelimab|DRUG: AG
ORR, Objective response rate, up to 20 weeks
PFS, Progression-free survival, up to 20 weeks|OS, Overall survival, 1 year|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Safety will be evaluated according to the NCI CTCAE Version 5.0. All observations pertinent to the safety of the study medication will be recorded on the CRF and included in the final report., through study completion, an average of 1 year
This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic therapy but have not undergone gemcitabine-based treatment.